Title: Method of evaluating cellutite and method of evaluating cellutite-effective drug using fibulin-3 and/or saccoglycan gamma as an indicator

Abstract: The present invention relates to a method of evaluating cellutite using fibulin-3 and/or saccoglycan gamma as an indicator in a harvested skin sample, and a method of evaluating a drug for improving, preventing or treating cellutite using fibulin-3 and/or saccoglycan gamma as an indicator in cultured cells.
Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator.

The present invention relates to a method of evaluating cellulite and a method of evaluating a cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator.

"Cellulite" (also named gynoid lipodystrophy) is a tissue that exhibits a rippled appearance of the skin mainly observed in the abdomen, thigh and buttock of women, and is especially a cosmetic problem, since it markedly impairs skin appearance. The pathogenesis of cellulite has not been fully elucidated academically or medically, and it is simply considered to be an accumulation of subcutaneous fat. According to a noninvasive analysis using MRI conducted by Mirrashed, F. and Querleux, B et al., morphological changes of adipose cells and adipose tissues were not observed in cellulite skin, but in cellulite skin, it was revealed that a part of the subcutaneous fat tissues projected deeply into the dermal layer (Non-patent Literature 1 and 2).

Since 40% of adult women have cellulite, and cellulite significantly impairs aesthetic appearance, there is a high demand for alleviating, preventing and treating cellulite, and products and aesthetic treatments intended for cellulite are already on the market both domestically and abroad. However, since the histological characteristics defining cellulite and the formation mechanism thereof have not been elucidated, such products
are usually directed to a product lacking effective data or simply slimming agents intended to reduce the amount of fat. Thus, there is very little at present that is really effective for reducing, preventing and treating cellulite, and no products specifically targeted for cellulite have been commercially available yet.

Although there are few references disclosing drugs and/or treatments for improving the appearance of cellulite along with experimental data on them, nicotinamide, conjugated linoleic acid and sulfocarboiose are disclosed as drugs that alleviate cellulite by applying on the affected cellulite site, along with experimental data (Patent Literature 1 and 2, and Non-patent Literature 8), and furthermore 1-4 MHz ultrasonic stimulation is disclosed as a treatment for alleviating cellulite (Patent Literature 3). While these references disclose data indicating the effect of alleviating cellulite, they do not clearly demonstrate its mechanism of action, and thus it is still unknown whether the reduction in cellulite is caused by the reduction in the amount of fat or whether a mechanism other than the reduction in fat works.

Researches on cellulite are mainly carried out by investigating skin tissue by means of noninvasive methods. However, in addition to a problem relating to a small number of test samples due to the nature of noninvasive methods, only fragmented information has been obtained. Thus, it is hardly said that cellulite has been systematically investigated. [Citation List] [Patent Literature]

[PLT 1] WO99/47112
[PLT 2] WO01/17498
[PLT 3] WO2004/080147
[Non-patent Literature]
[0007]

[NPL 10] Ana B R R et al., JEADV (2000) 14, 251-262

[Summary of Invention]

[Technical Problem]

[0008]

Under the above circumstances, there is a need for developing a method of evaluating cellulite, a drug intended to improve cellulite, and a method of evaluating such a drug.

[Solution to Problem]

[0009]

For the purpose of elucidating the histological characteristics and the formation mechanism of cellulite, more specifically of understanding the phenomena peculiar to cellulite on the tissue level using a variety of cellulite tissue and skin tissue, and furthermore for the purpose of elucidating the mechanism of appearance of the phenomena peculiar to cellulite using a molecular
biological method, the present inventors have conducted research.

[0010]

More specifically, 25 samples of skin biopsy tissues (hereinafter referred to as the cellulite skin) from the buttocks and the thighs of females exhibiting cellulite, and 19 samples of skin biopsy tissues (hereinafter referred to as the female control skin) from the buttocks and the thighs of females exhibiting no cellulite, were subjected to tissue analysis by using hematoxyline eosin stain, Sirius Red stain and Elastica van Gieson stain.

[0011]

This tissue analysis revealed that the papillary structure was significantly reduced in the cellulite skin, that the papillary dermis layer at the upper part of the dermis layer in the cellulite skin was thin compared to the female control skin, that while no marked changes were noted in the amount of collagen fibers containing collagen in cellulite, elastin fibers tended to be decreased and disturbed, and that while no morphological changes were found in the adipose cells and adipose tissues per se in the cellulite skin, localized changes in the form of fat projections were observed.

[0012]

From the new histological findings mentioned above, it was deduced that the cause of cellulite is twofold: the formation of fat projections inside the skin caused by the increased amount of fat, and changes such as the reduced elasticity and thinning of the dermis which otherwise should play a role of a cushion against the above projections, leading to the outward manifestation of ripples within the skin. Thus, it was found that cellulite formation may be associated with not only localized changes such as protruded fat but also changes in the dermis layer which so far attracted no attention. Therefore, a new finding was obtained which indicates that slimming drugs intended for weight reduction or
burning of fat are insufficient for improving cellulite whereas effective drugs or treatments coping with dermal changes may be required for cellulite improvement.

[0013]

In order to clarify the cause of changes in dermal fibers between the cellulite skin and the female control skin, the present inventors analyzed the expression level of genes of dermal fibroblasts, which constitute the most important cells of the dermis and determine the property thereof. More specifically, since analysis using RNA derived from the full-layer human tissue cannot precisely identify the properties of fibroblasts due to a kind of noise by cells and/or organs other than the fibroblasts that constitute the majority of the full-layer skin, the present inventors have used a Laser capture microdissection method (Non-patent Literature 4 and 5) to extract mRNA of dermal fibroblasts from skin tissue sections, and then gene microarrays have been carried out. As a result, the present inventors have succeeded in identifying a plurality of genes, the expression level of which vary between the cellulite skin and the female control skin.

[0014]

As a result of specifically examining the expression in the fibroblasts of the cellulite skin by using quantitative PCR for this plurality of genes, a markedly reduced expression of fibulin-3 and sarcoglycan gamma in the cellulite skin was confirmed (Figs. 4 and 6), and furthermore a similar trend was observed by immunohistological staining (Figs. 3 and 5).

[0015]

Fibulin-3 is one of the extracellular proteins involved in the formation of elastic fibers, and, as a common function, is known to be related to elastin fiber formation. (Non-patent Literature 6 and 7). On the other hand, although the function of sarcoglycan gamma, which is a proteoglycan, in the skin has not been demonstrated,
it is known as a common function that sarcoglycan gamma
protects sarcolemma from the phenotype of defective-
function individuals.

[0016]

Thus, the reduced expression of fibulin-3 is thought
to be involved in the cellulite formation, through the
abnormal formation of elastic fibers, specifically
elastin fibers, and the reduced expression of sarcoglycan
gamma is also thought to be involved in cellulite
formation, through the reduced function of protecting the
cell membrane in fibroblasts. However, the present
invention should not be limited by these mechanisms.

[0017]

Furthermore, when nicotinamide and conjugated
linoleic acid, which are known to improve the cellulite
appearance, were added to cultured cells, the present
inventors have found that these agents enhanced the
expression of fibulin-3 and sarcoglycan in a dose-
dependent manner. The present inventors, therefore,
concluded that these agents can recover the change in the
dermal fiber to normal by enhancing the expression of
fibulin-3 and sarcoglycan gamma which has been reduced in
the cellulite skin, thereby the cellulite appearance can
be improved (Figs. 7 and 8). In addition, when 1 MHz
ultrasonic stimulation, that is known to improve the
cellulite appearance, was applied to cultured cells, no
changes in the expression of fibulin-3 were found, but
the expression of sarcoglycan gamma was enhanced.
Therefore, the present inventors have concluded that the
change in the dermal fibers of cellulite was recovered to
normal through the enhancement of sarcoglycan gamma
eexpression (Fig. 9).

[0018]

Based on the above research and new findings
demonstrated by the present inventors, the present
inventors have concluded that the reduced expression of
fibulin-3 and sarcoglycan gamma is the cause of cellulite
formation, and thus have invented a method of evaluating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator, and a method of evaluating a drug for reducing, improving, preventing or treating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator.

[0019]

Thus, the present invention relates to the followings:

[1] A method of evaluating cellulite using the expression of fibulin-3 and/or sarcoglycan gamma in a harvested skin sample as an indicator.

[2] The evaluation method according to item [1], wherein said skin sample is dermis.

[3] The evaluation method according to item [1] or [2], wherein said skin sample is dermal fibroblasts.

[4] A method of evaluating a drug for improving, preventing or treating cellulite, using fibulin-3 and/or sarcoglycan gamma as an indicator in cultured cells.

[5] The evaluation method according to item [4] comprising the steps of:

adding a candidate drug to cultured cells;

determining the expression of fibulin-3 and/or sarcoglycan gamma; and

comparing the expression of fibulin-3 and/or sarcoglycan gamma in the control with the expression of fibulin-3 and/or sarcoglycan gamma after adding the candidate drug.


[7] The evaluation method according to any one of items [4] to [6], wherein when the amount expressed of fibulin-3 and/or sarcoglycan was enhanced in the above comparison step, the candidate drug is judged to have a cellulite-suppressing activity.

[8] A method of evaluating a cosmetic method for alleviating cellulite using the amount expressed of fibulin-3 and/or sarcoglycan gamma as an indicator.
[9] The evaluation method according to item [8] comprising the steps of:

determining the amount expressed of fibulin-3 and/or sarcoglycan gamma in the dermis of the skin before applying the cosmetic method;

applying the cosmetic method;

determining the expression of fibulin-3 and/or sarcoglycan gamma in the dermis of the skin after applying the cosmetic method; and

comparing the expression of fibulin-3 and/or sarcoglycan gamma in the dermis of the skin before and after applying the cosmetic method.

[10] The evaluation method according to item [9] wherein when the expression of fibulin-3 and/or sarcoglycan gamma is enhanced in the above comparison step, the cosmetic method is judged to have a cellulite-suppressing activity.

[11] The evaluation method according to item [10] wherein the determination of the expression of fibulin-3 and/or sarcoglycan gamma in the above dermis of the skin is conducted by quantitative PCR for a sample harvested by laser microdissection.

[Advantageous Effects of Invention]

[0020]

The present invention enables appropriately evaluating cellulite in a living body by using the expression of fibulin-3 and/or sarcoglycan gamma as an indicator. Also, by using the expression of fibulin-3 and/or sarcoglycan gamma as an indicator, the evaluation of a drug for the activity of suppressing or reducing cellulite becomes possible, and screening for a drug for treating, preventing or alleviating cellulite is possible.

[Brief Description of Drawings]

[0021]

[Fig. 1] Fig. 1 shows a photo of the appearances of the female control skin and the cellulite skin, and a photo
taken by staining the skin section with Elastica van Gieson staining. In the female control skin, elastin fibers are shown to be present densely arranged in the dermis, whereas in the cellulite skin elastin fibers are shown to be aggregated, and present sparsely.

[Fig. 2] Fig. 2 shows a graph of the degree of arrangement of elastin fibers. Score 1 means that the elastin fibers in photograph are disturbed, and that the amount thereof is low. As the score increases, the elastin fibers are arranged neatly, and the amount thereof are high.

[Fig. 3] Fig. 3 is a drawing showing immunostaining of fibulin-3 in the dermis. It was shown that the expression of fibulin-3 in the female control skin that does not suffer from cellulite is high, whereas the expression of fibulin-3 in the cellulite skin is low.

[Fig. 4] Fig. 4 is a drawing showing the result of determining the amount of mRNA of fibulin-3 in the dermis by quantitative PCR. It was shown that in the female control skin that does not suffer from cellulite the expression of fibulin-3 is high, whereas in the cellulite skin the expression of fibulin-3 is low.

[Fig. 5] Fig. 5 is a drawing showing immunostaining of sarcoglycan gamma in the dermis. It was shown that the expression of sarcoglycan gamma in the female control skin that does not suffer from cellulite is high, whereas the expression of sarcoglycan gamma in the cellulite skin is low.

[Fig. 6] Fig. 6 is a drawing showing the result of determining the amount of mRNA of sarcoglycan gamma in the dermis by quantitative PCR. It was shown that in the female control skin that does not suffer from cellulite the expression of sarcoglycan gamma is high, whereas in the cellulite skin the expression of sarcoglycan gamma is
low.

[Fig. 7]

Fig. 7 is a drawing showing changes in the expression of sarcoglycan gamma and fibulin-3 when conjugated linoleic acid was added to cultured fibroblasts.

[Fig. 8]

Fig. 8 is a drawing showing changes in the expression of sarcoglycan gamma and fibulin-3 when nicotinamide was added to cultured fibroblasts.

[Fig. 9]

Fig. 9 is a drawing showing changes in the expression of sarcoglycan gamma and fibulin-3 when 1 MHz ultrasonic stimulation was applied to cultured fibroblasts.

[Description of Embodiments]

[0022]

The present invention relates to a method of evaluating cellulite using the expression of fibulin-3 and/or sarcoglycan gamma in a harvested skin sample as an indicator. More specifically, the harvested sample is specifically a dermal tissue, more preferably dermal fibroblasts. The skin sample may be harvested by any method, but in terms of harvesting only the cells of interest, it is preferably harvested by laser microdissection.

[0023]

The method of evaluating cellulite of the present invention enables to evaluate cellulite in subjects suffering from cellulite of various degrees of severity, by determining the expression of fibulin-3 and/or sarcoglycan gamma in the skin samples obtained from the subjects and clarifying the relationship between the expression and the degree of severity in advance. As the degree of severity of cellulite, a method for classifying cellulite into 0 to 4 grades from the appearance of cellulite (NLP 1). The criteria of classification of the
degree of severity of cellulite is as listed in the following table:

<table>
<thead>
<tr>
<th>The severity of cellulite (Grade)</th>
<th>Skin Appearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No dimpling - smooth skin</td>
</tr>
<tr>
<td>1</td>
<td>Low number of small, shallow, visible dimples, sparsely located on the thighs</td>
</tr>
<tr>
<td>2</td>
<td>Moderate number of visible dimples (some large) on the thighs</td>
</tr>
<tr>
<td>3</td>
<td>Large number of visible dimples (many large) over most of the thighs</td>
</tr>
<tr>
<td>4</td>
<td>Cottage cheese appearance of skin</td>
</tr>
</tbody>
</table>

However, the classification of severity should not be limited to the above classification method, any classification can be used. For example, a method for classifying cellulite which is not based on skin appearance but on the histopathological and clinical observation is also known in the art (NLP10). According to this classification method, the severity of cellulite can be classified as described in the following table:
<table>
<thead>
<tr>
<th>The severity of cellulite (Grade)</th>
<th>Histopathological and Clinical Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No manifestation of cellulite both in skin appearance and inner skin tissue</td>
</tr>
<tr>
<td>1</td>
<td>The stage wherein there is no manifestation in skin appearance, no clinical change is observed, but several changes occurred in the inner skin</td>
</tr>
<tr>
<td>2</td>
<td>The stage wherein no relief alterations are present at rest, but after skin compression or after muscular contraction, pallor, decreased temperature and/or decreased elasticity is observed</td>
</tr>
<tr>
<td>3</td>
<td>The stage wherein a padded skin and/or an orange peel appearance is evident at rest, and palpable sensation of thin granulations in the deep levels, pain to palpation, decreased elasticity, pallor and/or decreased temperature is observed</td>
</tr>
<tr>
<td>4</td>
<td>The stage wherein there are the same characteristics as in grade III with more palpable, visible and painful nodules, adherence to the deep levels and an obvious wavy appearance of the skin surface</td>
</tr>
</tbody>
</table>

The evaluation of cellulite in a subject becomes possible by correlating each grade in these classification methods, etc., with the expression level of fibulin-3 and/or sarcoglycan gamma in advance.

[0024]

By using the expression of fibulin-3 and/or sarcoglycan gamma of the present invention as an indicator, cellulite at an early stage that is not visible on the skin surface can be diagnosed, thereby it is specifically useful in early discovery and prevention of cellulite. If early discovery of cellulite is possible, it enables any preventive measures to be taken before cellulite appears on the skin surface, i.e., before the appearance of the skin is badly affected, and thus it is most preferred.

[0025]
In another embodiment of the present invention, the present invention relates to a method of evaluating a drug for improving, preventing or treating cellulite by using fibulin-3 and/or sarcoglycan gamma as an indicator in cultured cells. More specifically, said method of evaluating a drug for improving, preventing or treating cellulite may comprise the following steps of:

adding a candidate drug to cultured cells;

determining the expression of fibulin-3 and/or sarcoglycan gamma; and

comparing the expression of fibulin-3 and/or sarcoglycan gamma in the control with the expression of fibulin-3 and/or sarcoglycan gamma after adding the candidate drug. Furthermore, when the expression of fibulin-3 and/or sarcoglycan gamma was enhanced, a step of determining that the candidate drug has a cellulite-suppressing activity may be included in or after the comparison step.

[0026]

The method of the present invention of evaluating a drug for improving, preventing or treating cellulite can be used in screening methods that permit the selection of a candidate drug having a cellulite-decreasing activity by using a candidate drug library containing a variety of candidate drugs, such as a compound library and an extract library. Thus, the method of the present invention of evaluating a drug for improving, preventing or treating cellulite is also directed to a screening method for drugs.

[0027]

In still another embodiment of the present invention, the present invention also relates to a method of evaluating a cosmetic method for alleviating and/or improving cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator. More specifically, the method of evaluating a cosmetic method comprises the steps of:

determining the expression of fibulin-3 and/or
sarcoglycan gamma in the dermis of the skin before applying the cosmetic method; applying the cosmetic method; determining the expression of fibulin-3 and/or sarcoglycan gamma in the dermis of the skin after applying the cosmetic method; and comparing the expression of fibulin-3 and/or sarcoglycan gamma in the dermis of the skin before and after applying the cosmetic method. The cosmetic method includes, but not limited to, application of a cosmetic, exercise, massage and ultrasonic treatment. When the expression of fibulin-3 and/or sarcoglycan gamma in the skin dermis, specifically fibroblasts of skin dermis, is enhanced after applying such a cosmetic method in comparison, it may be determined to be effective for alleviating and/or improving cellulite. Such a method of evaluating a cosmetic method may be provided not only by an individual, but also by a cosmetic sales person or an aesthetician other than a physician.

According to the present invention, the expression of fibulin-3 and/or sarcoglycan gamma to be used as an indicator can be determined by any method as long as it can be used in research for gene expression, for example, the determination of the amount of mRNA by quantitative PCR, the determination of the amount of mRNA by Northern blotting, and the determination of the amount of protein by Western blotting, ELISA or immunoprecipitation can be used. From the viewpoint of determining, use of a small amount of a sample harvested by laser microdissection, the determination of mRNA by quantitative PCR may be preferred.

In the method of the present invention, the expression of each of fibulin-3 and sarcoglycan gamma to be used as an indicator may be used individually or both of fibulin-3 and sarcoglycan gamma may be used as an
indicator.

[0030]

According to the present invention, the enhanced expression of fibulin-3 and/or sarcoglycan gamma means that relative to the expression of fibulin-3 and/or sarcoglycan gamma in the control, the expression of fibulin-3 and/or sarcoglycan gamma after adding a candidate drug is increased, preferably by 20% or more, more preferably 35% or more, and most preferably 50% or more. The increase in the expression may preferably be statistically significant.

[0031]

The dermis is a structure that lies underneath the epidermis, and the epidermis and the dermis are separated by the basal membrane. Fibroblasts are present in the dermis, and anatomically the dermis is composed of two layers of the papillary layer and the reticular layer.

[0032]

Cultured cells may be any cells as long as they are derived from skin cells. In view of cells related to cellulite, specifically dermal cells, more preferably cultured cells derived from fibroblasts of the dermis are preferred.

[Examples]

Example 1: Preparation of tissue sections

Tissue analysis was conducted using 25 samples (hereinafter referred to as the cellulite skin) of skin biopsy tissues derived from the buttocks and/or the thighs that exhibit the cellulite appearance, 19 samples (hereinafter referred to as the control skin) of skin biopsy tissues derived from the buttocks and/or the thighs that exhibit no cellulite appearance. All biopsy skin tissues were obtained from women. Biopsy skin tissues were embedded in an embedding medium OCT Compound (Sakura Finetek) for frozen tissues, and frozen-section slides were prepared using a frozen section preparation
instrument Cryostat (Leica).

[0034]

Example 2: Histochemical staining

After air-drying the tissue sections obtained in Example 1, each tissue section was subjected to Elastica van Gieson staining using Elastica van Gieson staining reagents (Merck) according to the method described in the instructions. From the result of Elastica van Gieson staining the alignment of elastin fibers in the dermis of cellulite skin was disturbed, and elastin fibers were aggregated and declined in comparison with control skin (Figure 1). In order to indicate this point obviously, fourteen samples of cellulite tissue sections and nine samples of control tissue sections were selected in random, and then they were scored in a blind trial by two observers. A score was determined to consist of five grades in advance, and when the score was 5, which was the best grade, elastin fibers were determined to be rich and to be aligned neatly in dermis, whereas when the score was 1, which was the lowest grade, elastin fibers were determined to be declined and disarrayed. The average of scores determined by two observers were divided into cellulite group and control group, and plotted respectively to determine tendency of scores. As a result, it was shown that the alignment of elastin fibers in the cellulite group was disturbed, and the elastin fibers in the cellulite group were aggregated and declined (Figure 2). From these results, the present inventors have concluded that dermal elastin fibers, which should play a role as a cushion against the ripples formed by fat projection in the dermis, are aggregated and reduced, thereby the ripples formed by fat projection in the dermis appear on the surface of skin to form cellulite.

[0035]

After the tissue sections obtained in Example 1 were air-dried, the immunohistological staining of fibulin-3
and sarcoglycan gamma was carried out as follows. After the tissue sections were fixed in 4% PFA for 15 minutes, the tissue sections were washed with PBS, and subjected to immunological staining using CSAII Biotin-free Tyramide Signal Amplification system (DAKO) according to DAKO's protocol. The antibodies used were anti-human fibulin-3 antibody (Santa Cruz) and anti-human sarcoglycan gamma antibody (Abcam). After DAB staining, the sections were mounted with a mounting agent and cover slip, and examined under microscope, such as a fluorescent microscope (Olympus) and photos were taken (Figs. 3 and 5).

Example 3: Extraction of trace RNA derived from fibroblasts of skin tissue sections, cDNA synthesis and amplification

Tissue section slides were prepared from tissue sections prepared with a frozen section preparation instrument Cryostat (Leica), by using PEN membrane glass slides (Molecular Device), and then stained using Frozen section staining kit (Arcturus). Subsequently, the tissue section slides were immersed for 30 seconds in 75% ethanol prepared with RNase-free distilled water (hereinafter referred to as the distilled water) immersed for 30 seconds in the distilled water, and then stained for 20 seconds in 100 µl of Histogene staining solution (Arcturus). After washing in the distilled water for 30 seconds, the slides were immersed and dehydrated in a series of 75%, 95% and 100% ethanol, and in xylene for 30 minutes, respectively. The decolorized and dehydrated tissue section slides were set in a laser microdissection instrument Veritas (Arcturus), and areas containing fibroblasts that are single cells localized in the dermis were microdissected while taking care not to contaminate with blood vessels or other auxiliary organs. Subsequently, extraction and purification of trace RNA were carried out by using Rneasy Plus Micro kit (Qiagen).
An area of the section containing microdissected fibroblasts was placed in a 500 μl tube containing 350 μl of RLT plus buffer containing 1% mercaptoethanol so as to extract RNA. Then, according to Qiagen's protocol, trace RNA was purified and isolated. After cooling on ice, it was transferred to a cDNA synthesis process. Using the WTOvation Pico System (NuGEN) according to the protocol provided, single stranded cDNA was synthesized based on the extracted RNA as the template, and then amplified.

cDNA synthesis and amplification were confirmed by using Bioanalyzer 2100 (Agilent). The concentration was determined by using a nucleic acid quantitation instrument Nanodrop (Thermo Scientific).

Example 4: Quantitative PCR of fibulin-3 and sarcoglycan gamma

Quantitative RT-PCR was carried out by using synthesized cDNA as the template, and further by using a reaction reagent LightCycler (registered trademark) FastStart DNA MasterPlus SYBR Green (Roche), and a reaction instrument LightCycler (Roche) or AB 7900 HT Fast Real-Time PCR System (Applied Biosystems). The condition for composition was as described in Roche's protocol. The annealing temperature of the primers was set at 60°C, and quantitated by using ΔΔCt method.

Sequence information of primer pairs used in quantitative PCR was as follows:

G3PDH forward: 5'-GAGTCAACGGATTTGCTGT-3'
reverse: 5'-TGGGATTTCCATTGATGACA-3'

18S rRNA forward: 5'-CGGTACCACATCCACAGGAA-3'
reverse: 5'-GCTGGAAATACCACGCGT-3'

Fibulin-3 forward: 5'-GCTCCGTTGTTATCCACGAAATCC-3'
reverse: 5'-CTGATCTGGAAGATGTCGTGATGCC-3'

sarcoglycan gamma forward: 5'-GAGGCCCAGAGAAATCAGTGCTAC-3'
reverse: 5'-CCATCTTTTTGTTACACACAAGTGCC-3'
The amount of cDNA in the control group was corrected, and the expression of fibulin-3 and sarcoglycan gamma was compared between the female control skin and the cellulite skin, respectively. The results are shown in Figs. 4 and 6.

Example 5: Experiment on the addition of known cellulite-improving drugs

Fibroblasts derived from human skin tissue were plated in a 24-well type I collagen-coated dish (IWAKI), and cultured to 70-80% confluence in a 10% bovine fetal serum-supplemented DMEM (Gibco/Invitrogen) under the condition of 37°C and 5% CO₂. After replacing with a serum-free medium for half a day, it was further replaced with a serum-free medium with varying concentrations of conjugated linoleic acid (Sigma) (0.001% v/v, 0.01% v/v) or nicotinamide (Sigma) (0.0005% v/v, 0.005% v/v). 24 hours later, RNA was recovered by using RNeasy mini kit (Qiagen) according to Qiagen's protocol. As a control, RNA prepared and recovered by substituting the medium with an intact serum-free medium, and recovering RNA 24 hours later was used. The concentration of the recovered RNA was determined using a nucleic acid quantitation instrument Nanodrop (Thermo Scientific). After adjusting the RNA concentration of the comparative control group at the same concentration, cDNA was synthesized from RNA using a cDNA synthesis kit High capacity cDNA reverse transcription kit (Applied Biosystems) according to an Applied Biosystems's protocol. Using a method described in Example 4, changes in the expression of fibulin-3 and the expression of sarcoglycan gamma when each known cellulite-improving drug was used are shown in Fig. 7 and Fig. 8.

Example 6: Sonication of cultured cells

Fibroblasts derived from human skin tissue were plated in a 35 mm well dish (Becton Dickinson), and
cultured to 70-80% confluence in a 10% bovine fetal serum-supplemented DMEM (Gibco/Invitrogen) under the condition of 37°C and 5% CO₂. After replacing with a serum-free medium for half a day, it was further replaced with a fresh serum-free medium, and subjected to 1 MHz ultrasonic stimulation at a distance of 0.5 mm using an ultrasonic cosmetic machine (Matsushita Denko). The stimulation time was set at a short 20 seconds, considering that the cells are directly stimulated. After 24 hours of stimulation, RNA was recovered according to Qiagen's protocol. The concentration of the recovered RNA was determined using a nucleic acid quantitation instrument Nanodrop (Thermo Scientific). After adjusting the RNA concentration of the comparative control group at the same concentration, cDNA was synthesized from RNA using a cDNA synthesis kit High capacity cDNA reverse transcription kit (Applied Biosystems) according to an Applied Biosystems's protocol. Using a method described in Working Example 4, changes in the expression of fibulin-3 and the expression of sarcoglycan gamma when sonication was carried out are shown in Fig. 9.
[Claim 1]

A method of evaluating cellulite using the expression of fibulin-3 and/or sarcoglycan gamma in a harvested skin sample as an indicator.

[Claim 2]

The evaluation method according to claim 1 wherein said skin sample is dermis.

[Claim 3]

The evaluation method according to claim 1 wherein said skin sample is dermal fibroblasts.

[Claim 4]

A method of evaluating a drug for improving, preventing or treating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator in cultured cells.

[Claim 5]

The evaluation method according to claim 4 comprising the steps of:

adding a candidate drug to cultured cells;

determining the expression of fibulin-3 and/or sarcoglycan gamma; and

comparing the expression of fibulin-3 and/or sarcoglycan gamma in the control with the expression of fibulin-3 and/or sarcoglycan gamma after adding the candidate drug.

[Claim 6]

The evaluation method according to claim 4 or claim 5 wherein said cultured cells are dermal fibroblasts.

[Claim 7]

The evaluation method according to claim 5 or 6 wherein when the expression of fibulin-3 and/or sarcoglycan gamma was enhanced in the above comparison step, the candidate drug is judged to have a cellulite-suppressing activity.
Fig. 1

the female control skin

the cellulite skin

200um
Fig. 2

![Plot showing comparison between control and cellulite scores](image)
Fig. 3

the female control skin

the cellulite skin

200um
Fig. 4

[Diagram showing Fibulin-3/18S rRNA levels in control and cellulite samples]

Control

Cellulite
Fig. 5

the female control skin

the cellulite skin

50um
Fig. 6

![Diagram showing the comparison between control and cellulite in SGCG/18S rRNA levels. The control group has a significantly higher value, indicated by a shaded bar, while the cellulite group has a much lower value, represented by a solid bar.](image-url)
Fig. 9
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

INV. G01N33/50
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
* "A" document defining the general state of the art which is not considered to be of particular relevance
* "E" earlier application or patent but published on or after the international filing date
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* "O" document referring to an oral disclosure, use, exhibition or other means
* "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search
22 March 2013

Date of mailing of the international search report
08/04/2013

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax. (+31-70) 340-3016

Authorized officer
R. von Eggelkraut-G.
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>C. RONA ET AL: &quot;Testing anticellulite products&quot;,</td>
<td>1-7</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (continuation of second sheet) (April 2005)
### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>